Merck & Co., Inc. (MRK) Reports In-Line Q4 EPS; Guides In-Line

February 5, 2014 7:03 AM EST
Merck & Co., Inc. (NYSE: MRK) reported Q4 EPS of $0.88, in-line with the analyst estimate of $0.88. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $11.39 billion.

Merck & Co., Inc. sees FY2014 EPS of $3.35-$3.53, versus the consensus of $3.48. Merck & Co., Inc. sees FY2014 revenue of $42.4-43.2 billion, versus the consensus of $43.35 billion.

In 2013 we took decisive actionn to sharpen our focus, reduce our cost structure and advance our innovative research and development,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “This year we are excited about the potential of our near- and long-term pipeline, poised for long-term growth and committed to providing continued value to patients, customers and our shareholders.”

For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings, Management Comments

Related Entities